Research programme: small molecule cancer therapeutics - Peloton Therapeutics

Drug Profile

Research programme: small molecule cancer therapeutics - Peloton Therapeutics

Alternative Names: PT 2399

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer Peloton Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Sep 2016 Preclinical development is ongoing in USA
  • 06 Sep 2016 Pharmacodynamics data from a preclinical trial in Cancer released by Peloton Therapeutics
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top